^
Association details:
| Biomarker: | HRAS mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | AZ 628 (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PI3K pathway dependencies in endometrioid endometrial cancer cell lines
Excerpt:
Three EEC cells showed SF50s below 1μM when treated with the selective RAF inhibitor AZD628 (Fig. 2D), and the presence of KRAS, HRAS or NRAS mutations was significantly associated with response to this agent (P=0.028), whilst KRAS mutations alone failed to show a statistically significant association (P=0.143).
DOI:
10.1158/1078-0432.CCR-12-3815
